Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Aurelius Gabriel Omlin"'
Autor:
Elena Trevisi, Kira-Lee Koster, Karl Heinimann, Ursina Zuerrer, Fabio Turco, Davide Giovanni Bosetti, Ilaria Colombo, Silvia Maitz, Marta Nerone, Aurelius Gabriel Omlin, Ursula Vogl, Silke Gillessen, Rossella Graffeo
Publikováno v:
Journal of Clinical Oncology. 41:383-383
383 Background: The clinical role of germline testing (GT) for prostate cancer (PC) is rapidly increasing due to the growing implications of precision medicine in metastatic disease, where genetic results can address eligibility for novel targeted tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1367e3ed5ef6e443cc0e7d8bde0c9963
https://doi.org/10.1200/jco.2023.41.6_suppl.383
https://doi.org/10.1200/jco.2023.41.6_suppl.383
Autor:
Alan Dal Pra, Stephane Supiot, Katrin Gysel, Thomas Zilli, Richard Cathomas, Thomas Reynaud, Pascal Pommier, Paul Martin Putora, Davide Giovanni Bosetti, Matthias Guckenberger, Guido Hildebrandt, Sabrina Chiquet, Meryem Brihoum, Alexandros Papachristofilou, Stefanie Hayoz, Pirus Ghadjar, Daniel Rudolf Zwahlen, Silke Gillessen, Aurelius Gabriel Omlin, Daniel M. Aebersold
Publikováno v:
Journal of Clinical Oncology. 41:353-353
353 Background: Pre-clinical and retrospective clinical data support an interaction of metformin (MET) and radiotherapy. Thus, MET may represent a cost-effective means to improve radiotherapy outcomes. We sought to investigate whether MET increases t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2665ff3e8d7520a4870dbf51badd265d
https://doi.org/10.1200/jco.2023.41.6_suppl.353
https://doi.org/10.1200/jco.2023.41.6_suppl.353
Autor:
Semini Sumanasuriya, Aurelius Gabriel Omlin, Andrew J. Armstrong, Gerhardt Attard, Kim N. Chi, Charlotte L Bevan, David J. Waugh, Maarten J Ijzerman, Bram De Laere, Martijn P. Lolkema, David Lorente, Jun Luo, Niven Mehra, David Olmos, Howard I. Scher, Howard R. Soule, Nikolas H. Stoecklein, Leon W M M Terstappen, Johann S. De Bono
Publikováno v:
Journal of Clinical Oncology. 36:299-299
299 Background: The need for validated circulating biomarkers is well recognised in advanced prostate cancer (PCa). Circulating biomarkers evaluating plasma cell-free nucleic acids and circulating tumour cells are being investigated for their clinica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::99ec0b27b6447c23f72ddf8b64d7d92d
https://doi.org/10.1200/jco.2018.36.6_suppl.299
https://doi.org/10.1200/jco.2018.36.6_suppl.299